Pentwater Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-100,000
| Closed | -$986K | – | 80 |
|
|
2023
Q4 | $986K | Hold |
100,000
| – | – | 0.01% | 57 |
|
|
2023
Q3 | $765K | Sell |
100,000
-265,000
| -73% | -$2.03M | ﹤0.01% | 61 |
|
|
2023
Q2 | $2.73M | Sell |
365,000
-55,000
| -13% | -$411K | 0.02% | 54 |
|
|
2023
Q1 | $2.8M | Buy |
420,000
+20,000
| +5% | +$133K | 0.03% | 59 |
|
|
2022
Q4 | $3.08M | Buy |
400,000
+100,000
| +33% | +$771K | 0.05% | 45 |
|
|
2022
Q3 | $3.19M | Hold |
300,000
| – | – | 0.04% | 65 |
|
|
2022
Q2 | $2.44M | Hold |
300,000
| – | – | 0.03% | 81 |
|
|
2022
Q1 | $2.15M | Buy |
300,000
+20,000
| +7% | +$143K | 0.03% | 76 |
|
|
2021
Q4 | $4.8M | Buy |
280,000
+15,000
| +6% | +$257K | 0.05% | 64 |
|
|
2021
Q3 | $6.1M | Buy |
265,000
+12,500
| +5% | +$288K | 0.06% | 65 |
|
|
2021
Q2 | $9.22M | Buy |
+252,500
| New | +$9.22M | 0.08% | 56 |
|